Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Credit Suisse Downgrades Arco Platform to Neutral, Lowers Price Target to $18

Credit Suisse analyst Daniel Federle downgrades Arco Platform (NASDAQ:ARCE) from Outperform to Neutral and lowers the price target from $27 to $18.
byBenzinga Newsdesk
August 26, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Credit Suisse analyst Daniel Federle downgrades Arco Platform (NASDAQ:ARCE) from Outperform to Neutral and lowers the price target from $27 to $18.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Initial Phase 1 Dose Escalation Data For ORIC-533 In Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity And Strong Safety Profile Supporting Potential For Combination Development At The 65th American Society Of Hematology Annual Meetin…

By Benzinga Newsdesk
December 11, 1:05 PM
Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose

ORIC